ZA200510331B - Platelet glycoprotein IB alpha variant fusion polypeptides and methods of use thereof - Google Patents

Platelet glycoprotein IB alpha variant fusion polypeptides and methods of use thereof

Info

Publication number
ZA200510331B
ZA200510331B ZA200510331A ZA200510331A ZA200510331B ZA 200510331 B ZA200510331 B ZA 200510331B ZA 200510331 A ZA200510331 A ZA 200510331A ZA 200510331 A ZA200510331 A ZA 200510331A ZA 200510331 B ZA200510331 B ZA 200510331B
Authority
ZA
South Africa
Prior art keywords
methods
fusion polypeptides
platelet glycoprotein
variant fusion
alpha variant
Prior art date
Application number
ZA200510331A
Other languages
English (en)
Inventor
Shaw Gray
Dianne S Sako
Kumar Ravindra
Xu Jin
Original Assignee
Wyeth Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Wyeth Corp filed Critical Wyeth Corp
Publication of ZA200510331B publication Critical patent/ZA200510331B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/745—Blood coagulation or fibrinolysis factors
    • C07K14/755—Factors VIII, e.g. factor VIII C (AHF), factor VIII Ag (VWF)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Zoology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Cell Biology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Epidemiology (AREA)
  • Diabetes (AREA)
  • Peptides Or Proteins (AREA)
ZA200510331A 2003-06-11 2004-06-14 Platelet glycoprotein IB alpha variant fusion polypeptides and methods of use thereof ZA200510331B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US47752503P 2003-06-11 2003-06-11

Publications (1)

Publication Number Publication Date
ZA200510331B true ZA200510331B (en) 2007-03-28

Family

ID=33551724

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA200510331A ZA200510331B (en) 2003-06-11 2004-06-14 Platelet glycoprotein IB alpha variant fusion polypeptides and methods of use thereof

Country Status (16)

Country Link
US (2) US7727535B2 (xx)
EP (2) EP2522677A1 (xx)
JP (1) JP2007537710A (xx)
KR (1) KR20060022261A (xx)
CN (1) CN100436480C (xx)
AU (1) AU2004247737B2 (xx)
BR (1) BRPI0411289A (xx)
CA (1) CA2530972A1 (xx)
HK (1) HK1095152A1 (xx)
IL (2) IL172337A (xx)
MX (1) MXPA05013509A (xx)
NO (1) NO20060093L (xx)
NZ (1) NZ544165A (xx)
RU (1) RU2403262C2 (xx)
WO (1) WO2004111089A2 (xx)
ZA (1) ZA200510331B (xx)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7534595B2 (en) * 2006-06-12 2009-05-19 Biomarin Pharmaceutical Inc. Compositions of prokaryotic phenylalanine ammonia-lyase and methods of using compositions thereof
US11535673B2 (en) * 2007-04-05 2022-12-27 President and Fellows of Harvard CoHege Chimeric activators: quantitatively designed protein therapeutics and uses thereof
DE102007031708A1 (de) * 2007-07-06 2009-01-08 Dade Behring Marburg Gmbh Bestimmung der von Willebrand Faktor-Aktivität in Abwesenheit von Ristocetin
WO2009026551A1 (en) 2007-08-23 2009-02-26 Bloodcenter Of Wisconsin, Inc. Methods and kits for measuring von willebrand factor
EP3456338B1 (en) * 2011-11-15 2020-07-29 The Walter and Eliza Hall Institute of Medical Research Soluble cd52 for use in the treatment or prevention of multiple sclerosis or rheumatoid arthritis
CA2871057A1 (en) * 2011-12-23 2013-06-27 Vasculogics, Inc. Compositions and methods for treatment of thrombosis and for prolonging survival of stored platelets
EP2919013B1 (de) * 2014-03-11 2016-11-02 Siemens Healthcare Diagnostics Products GmbH Verfahren zur Detektion von Modulatoren der GPIb-Thrombin-Interaktion
US10308697B2 (en) 2014-04-30 2019-06-04 President And Fellows Of Harvard College Fusion proteins for treating cancer and related methods
KR20170010863A (ko) 2014-07-01 2017-02-01 화이자 인코포레이티드 이중특이성 이종이량체성 디아바디 및 이의 용도
JP7373993B2 (ja) * 2018-02-20 2023-11-06 エフ． ホフマン－ラ ロシュ アーゲー 組換えＧｐＩｂα受容体タンパク質を含む組成物
CN113264995A (zh) * 2021-05-26 2021-08-17 苏州大学 一种血小板GPIbα蛋白相关的抗原表位肽及其应用
WO2023007182A1 (en) * 2021-07-29 2023-02-02 The University Of Birmingham Protein interaction inhibitors
WO2023109903A1 (zh) * 2021-12-15 2023-06-22 上海循曜生物科技有限公司 治疗血小板减少的产品及方法

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5340727A (en) * 1987-11-17 1994-08-23 The Scripps Research Institute GPIbα fragments and recombinant DNA expression vectors
IL88308A0 (en) * 1987-11-17 1989-06-30 Scripps Clinic Res Peptides that block the binding of von willebrand factor
US4899195A (en) * 1988-01-29 1990-02-06 Ushio Denki Method of exposing a peripheral part of wafer
US5225538A (en) * 1989-02-23 1993-07-06 Genentech, Inc. Lymphocyte homing receptor/immunoglobulin fusion proteins
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5194743A (en) * 1990-04-06 1993-03-16 Nikon Corporation Device for positioning circular semiconductor wafers
JP2874280B2 (ja) * 1990-05-16 1999-03-24 株式会社ニコン 周縁露光装置及び周縁露光方法
US6136310A (en) 1991-07-25 2000-10-24 Idec Pharmaceuticals Corporation Recombinant anti-CD4 antibodies for human therapy
US5317097A (en) * 1991-10-07 1994-05-31 The Research Foundation Of State University Of New York Mutations in the gene encoding the α chain on platelet glycoprotein IB
US6277975B1 (en) * 1992-10-23 2001-08-21 Genetics Institute, Inc. Fusions of P-selectin ligand protein and polynucleotides encoding same
US5516964A (en) 1994-01-21 1996-05-14 Sun Company, Inc. (R&M) Hydrocarbon isomerization using solid superacid catalysts comprising platinum metal
TW316322B (xx) * 1995-10-02 1997-09-21 Ushio Electric Inc
JP3237522B2 (ja) * 1996-02-05 2001-12-10 ウシオ電機株式会社 ウエハ周辺露光方法および装置
JP3735921B2 (ja) * 1996-02-07 2006-01-18 三菱ウェルファーマ株式会社 ＧＰＩｂ・脂質複合体およびその用途
DK1068241T3 (da) 1998-04-02 2008-02-04 Genentech Inc Antistofvarianter og fragmenter deraf
ATE417068T1 (de) 1998-04-23 2008-12-15 Ajinomoto Kk Stoff mit antithrombotischer aktivität und verfahren zur bestimmung von glycokallidin
AR035779A1 (es) 2001-02-06 2004-07-14 Genetics Inst Llc Polipeptidos de fusion derivados de glicoproteina ib alfa de plaqueta y metodos de uso de los mismos

Also Published As

Publication number Publication date
BRPI0411289A (pt) 2006-08-01
US7727535B2 (en) 2010-06-01
MXPA05013509A (es) 2006-04-05
AU2004247737B2 (en) 2009-04-23
JP2007537710A (ja) 2007-12-27
AU2004247737A1 (en) 2004-12-23
KR20060022261A (ko) 2006-03-09
EP1636266A2 (en) 2006-03-22
NO20060093L (no) 2006-03-01
HK1095152A1 (en) 2007-04-27
CA2530972A1 (en) 2004-12-23
CN1823090A (zh) 2006-08-23
RU2006100306A (ru) 2006-06-10
IL172337A (en) 2012-07-31
US20050089888A1 (en) 2005-04-28
EP2522677A1 (en) 2012-11-14
WO2004111089A3 (en) 2005-05-12
NZ544165A (en) 2008-12-24
IL220272A0 (en) 2012-07-31
US20110039780A1 (en) 2011-02-17
WO2004111089A2 (en) 2004-12-23
CN100436480C (zh) 2008-11-26
RU2403262C2 (ru) 2010-11-10

Similar Documents

Publication Publication Date Title
HK1095152A1 (en) Platelet glycoprotein ib alpha variant fusion polypeptides and methods of use thereof
EP1636250A4 (en) SELF-ORGANIZING PEPTIDES CONTAINING MODIFICATIONS AND METHOD FOR THEIR USE
ZA200700643B (en) RAGE fusion proteins and methods of use
EP1501514A4 (en) PROTEIN-KINASE MODULATORS AND METHODS OF USE
ZA200700641B (en) Rage fusion proteins and methods of use
IL166632A0 (en) Alpha-fetoprotein immu31 antibodies and fusion proteins and methods of use thereof
EP1663278A4 (en) EPO MIMETIC PEPTIDES AND FUSION PROTEINS
IL169638A0 (en) Soluble fcyr fusion proteins and methods of use thereof
SI2418220T1 (sl) Interferon alfa protitelesa in njihova uporaba
HK1072373A1 (en) Virus coat protein/receptor chimeras and methods of use
EP1608318A4 (en) CXCR4 ANTAGONISTS AND METHODS OF USE
SI1673460T1 (sl) Rekombinantna cepiva in njihova uporaba
EP1588991A4 (en) CERAMIC COMPOSITE MATERIAL FOR OPTICAL CONVERSION AND USE THEREOF
IL158751A0 (en) Recombinant fusion proteins and the trimers thereof
IL176895A0 (en) Purified interleukin-15/fc fusion protein and preparation thereof
EP1451217A4 (en) NEW PEPTIDES PROVIDING ENVIRONMENTAL RESISTANCE, AND FUSION PROTEINS CONTAINING THOSE PEPTIDES
PL376673A1 (pl) Białka fuzyjne mutein interferonu alfa o ulepszonych właściwościach
IL157264A0 (en) Platelet glycoprotein ib alpha fusion polypeptides and methods of use thereof
AU2003272423A8 (en) Centrosome proteins and uses thereof
EP1633398A4 (en) PREPARATION AND APPLICATION OF BIFUNCTIONAL ANTI-TUMOR HYBRID PROTEINS
HK1209050A1 (en) Survivin-derived peptides and use thereof
EP1423402A4 (en) NOVEL ANALOGUES OF POLYPEPTIDES AND HYBRID PROTEINS AND METHODS OF USE
AU2002322416A1 (en) Gfp fusion proteins and their use
EP1541677A4 (en) NEW PROTEINS AND USE THEREOF
IL166102A0 (en) Beta-sheet breaking peptides and their use